Cuba's LBF Lab Maintains Production of Vital Dialysis Concentrates Amidst Blockade

Despite the persistent and damaging effects of the U.S. blockade, Cuba's pharmaceutical industry, specifically the LBF laboratory within BioCubaFarma, demonstrates remarkable resilience in maintaining the production of critical hemodialysis concentrates and parenteral solutions. This unwavering commitment ensures that patients with chronic kidney disease across the nation receive the life-saving treatments they require.

Granma highlights the extraordinary efforts undertaken by the state to secure the necessary human, material, and financial resources, as well as energy for production and transportation. The laboratory's director, Jorge Oreste Fernández Batista, emphasizes the efficient use of resources, including imported components, and the crucial role of energy carriers in this process.

“

guarantees the volumes demanded by the National Health System, with the corresponding human, material, and financial resources, as well as the energy backup for elaboration and transportation.

The article underscores the challenges posed by the blockade, which limits financing for essential raw materials and inputs for oral rehydration salts, parenteral solutions, and vitamin complexes like Nutriforte. However, it also showcases Cuba's proactive approach to overcoming these obstacles through the promotion of renewable energy sources, conservation, recycling, and the introduction of electric vehicles and alternative production methods.

Furthermore, the article notes the dedication of the workforce, evidenced by the LBF laboratory's recognition as a National Vanguard by the National Union of Workers in Education, Science, and Sports for the fifth consecutive time. This achievement reflects not only the company's operational success but also the strong spirit of its employees in the face of external pressures.

“

implies an efficient use of resources, not a few imported, and of energy carriers.